Bronchoscopy for bevacizumab-related hemoptysis

Area of Science:

• Oncology
• Pulmonology
• Vascular Biology

Background:

• Bevacizumab is an anti-angiogenic therapy targeting vascular endothelial growth factor (VEGF) for cancer treatment.
• Hemoptysis is a severe adverse effect associated with bevacizumab therapy.
• VEGF inhibition may contribute to lung tissue damage leading to hemoptysis.

Observation:

• A patient receiving bevacizumab experienced life-threatening hemoptysis.
• Bronchoscopic examination revealed findings associated with the adverse event.
• The hemoptysis was successfully managed using interventional pulmonology techniques.

Findings:

• Bevacizumab-induced hemoptysis can occur due to VEGF pathway interference.
• Rigid bronchoscopy identified the source of bleeding.
• Laser photocoagulation effectively controlled the hemorrhage.

Implications:

• This case highlights a critical adverse event of bevacizumab, emphasizing the need for vigilant monitoring.
• Interventional bronchoscopic procedures offer a viable treatment option for managing severe bevacizumab-related hemoptysis.
• Understanding VEGF's role in lung tissue integrity is crucial for optimizing anti-angiogenic cancer therapies.